Celldex Therapeutics
CLDX
228 hedge funds and large institutions have $2.31B invested in Celldex Therapeutics in 2026 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 67 increasing their positions, 58 reducing their positions, and 14 closing their positions.
329% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 14
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
23% more funds holding
Funds holding: 185 → 228 (+43)
16% more capital invested
Capital invested by funds: $1.99B → $2.31B (+$320M)
16% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 58
0.84% less ownership
Funds ownership: 109.85% → 109.01% (-0.84%)
38% less call options, than puts
Call options by funds: $3.79M | Put options by funds: $6.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$40.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.1M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$12.6M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$11.1M |
| 5 |
EP
Eversept Partners
New York
|
+$9.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$65.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.6M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$27.4M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$16.8M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$16.5M |
CLDX Hedge Fund Activity: Q1 2026 in Review
228 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2026, worth a combined $2.31B — up 16% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new CLDX positions and 14 closed out — a net gain of 46 holders — while 67 added to existing stakes and 58 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $40.1M. The largest seller was Bellevue Group, cutting an estimated $65.9M.
- 228 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2026, up from 185 in Q4 2025.
- Funds reported $2.31B of Celldex Therapeutics stock for Q1 2026, up 16% quarter-over-quarter.
- 60 funds opened new Celldex Therapeutics positions in Q1 2026 and 14 closed out, a net change of +46 holders.
- The largest Celldex Therapeutics buyer in Q1 2026 was Point72 Asset Management, an estimated $40.1M added.
- The largest Celldex Therapeutics seller in Q1 2026 was Bellevue Group, an estimated $65.9M sold.
Based on aggregated 13F filings for Q1 2026.